Expert Panel Issues Guidelines on GLP-1 Use in Pregnancy
An international expert panel published systematic review and consensus guidelines on incretin-based medications (GLP-1s including semaglutide, liraglutide, dulaglutide, exenatide) in women's reproductive health, covering use before, during, and after pregnancy. The guidance, published in Obesity Reviews and based on 34 studies, provides counseling recommendations for clinicians treating patients on these medications. The guidelines address an emerging clinical question as GLP-1 use expands among women of reproductive age, including Medicaid beneficiaries with obesity and diabetes.
Medicaid covers approximately 42% of births nationally and serves high rates of women with obesity and diabetes who may be prescribed GLP-1s, making clinical guidance on pregnancy safety and medication management directly relevant to state prenatal care protocols and managed care quality measures.
Maternal · Pharmacy · Managed Care
You might also like